RxDoctor Payments Data

Sara Colon Santiago, MD

Internal Medicine · Moca, PRNPI 1871836643

Payments from drug & device makers

$656in general payments, 2019–2025

Across 40 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$238
  • Novo Nordisk$86
  • Lilly USA, LLC$83
  • Pfizer$83
  • Boehringer Ingelheim$73
  • Arbor Pharmaceuticals, Inc.$26
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$656100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$656 in reported general payments places this provider in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,886
Medicare patients
22
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$182,536
EliquisApixaban110$121,442
JardianceEmpagliflozin64$74,231
FarxigaDapagliflozin Propanediol56$61,019
JanuviaSitagliptin Phosphate44$47,065
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$42,995
TradjentaLinagliptin41$40,063
TrulicityDulaglutide33$30,870
EntrestoSacubitril/Valsartan21$21,005
MyrbetriqMirabegron22$20,006
JanumetSitagliptin Phos/Metformin Hcl19$19,521
XareltoRivaroxaban21$18,863
SymbicortBudesonide/Formoterol Fumarate41$13,941
LinzessLinaclotide13$13,242
Lantus SolostarInsulin Glargine,hum.Rec.Anlog114$12,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$86$182,536145 claims
PfizerEliquis$83$121,442110 claims
Boehringer IngelheimJardiance, Tradjenta$73$114,294105 claims
AstraZenecaFarxiga, Symbicort$238$74,96097 claims
GSKTrelegy Ellipta, Breo Ellipta$14$48,68957 claims
Lilly USA, LLCTrulicity, Mounjaro$83$41,82044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Moca

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →